Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity

Cabozantinib, a multiple tyrosine kinase inhibitor targeting AXL, vascular endothelial growth factor receptor (VEGFR), and MET, is used clinically to treat certain cancers, including hepatocellular carcinoma. This study aimed to assess the impact of cabozantinib on liver fibrosis and hepatocarcinoge...

Full description

Bibliographic Details

Published in:	Heliyon
Main Authors:	Takuya Matsuda, Kosuke Kaji, Norihisa Nishimura, Shohei Asada, Aritoshi Koizumi, Misako Tanaka, Nobuyuki Yorioka, Yuki Tsuji, Koh Kitagawa, Shinya Sato, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Format:	Article
Language:	English
Published:	Elsevier 2024-10-01
Subjects:	Angiogenesis Liver fibrosis MASH Inflammation Hepatocarcinogenesis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024146786